NEUROENDOCRINE CANCER
Clinical trials for NEUROENDOCRINE CANCER explained in plain language.
Never miss a new study
Get alerted when new NEUROENDOCRINE CANCER trials appear
Sign up with your email to follow new studies for NEUROENDOCRINE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug BL-M14D1 targets tough cancers in early human trial
Disease control Recruiting nowThis early-stage trial is testing a new drug called BL-M14D1 in about 120 people with advanced small cell lung cancer or other neuroendocrine cancers that have spread or cannot be removed. The drug works by homing in on a protein called DLL3 found on these cancer cells and delive…
Matched conditions: NEUROENDOCRINE CANCER
Phase: PHASE1 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug duo targets hard-to-treat cancers in early trial
Disease control Recruiting nowThis study tests a combination of two experimental drugs, ZGGS18 and ZG005, in people with advanced solid tumors (cervical, liver, neuroendocrine, or lung cancer) that no longer respond to standard treatments. The main goals are to check safety, find the best dose, and see if the…
Matched conditions: NEUROENDOCRINE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New biologic ZG006 targets tough lung and neuroendocrine cancers
Disease control Recruiting nowThis study tests a new biologic drug called ZG006 in people with advanced small cell lung cancer or neuroendocrine carcinoma. The trial has two parts: first, finding a safe dose (Phase 1), then testing how well it shrinks tumors (Phase 2). About 265 participants will receive ZG00…
Matched conditions: NEUROENDOCRINE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New scan could spot hidden cancers
Diagnosis Recruiting nowThis study is testing a new type of PET scan that targets a protein called DLL3, found on some neuroendocrine cancer cells. The goal is to see if this scan can find tumors more accurately than current imaging methods. About 60 adults with suspected or confirmed neuroendocrine can…
Matched conditions: NEUROENDOCRINE CANCER
Phase: NA • Sponsor: The First Affiliated Hospital of Xiamen University • Aim: Diagnosis
Last updated Jun 27, 2026 11:00 UTC